The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes

Endocrine Practice

Volumn 19, Issue 2, 2013, Pages 196-201

  Lane, Wendy S ^a   Weinrib, Stephen L ^a   Rappaport, Jonathan M ^a   Hale, Christopher B ^a   Farmer, Lynley K ^a   Lane, Rebecca S ^a  

^a Mountain Diabetes and Endocrine Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; LIRAGLUTIDE; METFORMIN; PIG INSULIN; SULFONYLUREA; U 500 INSULIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DEATH; DIABETIC PATIENT; DISEASE DURATION; DRUG DOSE INCREASE; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH INSURANCE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN INFUSION; INSULIN PUMP; INSULIN RESISTANCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RETROSPECTIVE STUDY; STOMACH BYPASS; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INSULIN INFUSION SYSTEMS; INSULIN RESISTANCE; INSULIN, REGULAR, HUMAN; MALE; MIDDLE AGED; NORTH CAROLINA; OBESITY; OBESITY, MORBID; OFF-LABEL USE; OSMOLAR CONCENTRATION; RETROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 84877112465     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12226.OR     Document Type: Article

References (16)

1. de la Peña A, Riddle M, Morrow LA, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34: 2496-2501.
2. Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15:71-79.
3. Zeismer AE, Kelly KC, Guerra PA, George KG, Dunn FL. U-500 regular insulin use in insulin-resistant type 2 diabetic veteran patients. Endocr Pract. 2012;18:34-38.
4. Dailey AM, Williams S, Taneja D, Tannock LR. Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract. 2010;88:259-264.
5. Lowery JB, Donihi AC, Korytkowski MT. U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes. Diabetes Technol Ther. 2012;14:505-507.
6. Lane WS, Weinrib SL, Rappaport JM, Przestrzelski T. A prospective trial of U-500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. Endocr Pract. 2010;16:778-784.
7. Knee TS, Seidensticker DF, Walton JL, Solberg LM, Lasseter DH. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract. 2003;9:181-186.
8. Bulchandani DG, Konrady T, Hamburg MS. Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr Pract. 2007;13:721-725.
9. Davidson MB, Navar MD, Echeverry D, Duran P. U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care. 2010;33:281-283.
10. Wafa WS, Khan MI. Use of U-500 regular insulin in type 2 diabetes. Diabetes Care. 2006;29:2175-2176.
11. Dailey AM, Gibert JA, Tannock LR. Durability of glycemic control using U-500 insulin. Diabetes Res Clin Pract. 2012;95:340-344.
12. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-1687.
13. El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205:2409-2417.
14. Trence DL, Hirsch IB. Motherhood, apple pie, hemoglobin A1c and the DCCT. Endocr Pract. 2012;18:78-84.
15. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281: 2005-2012.
16. Khan SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.